Otros idiomas Mustang Bio, Inc.

Acciones

MBIO

US62818Q2030

Tiempo real estimado Cboe BZX Otros sitios de cotización 20:33:46 09/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,278 ^USD	-2,83 %		-4,78 %	-79,33 %

30/04	Mustang Bio fija el precio de una oferta pública de 16,9 millones de acciones, acompañadas de warrants	MT
28/03	Mustang Bio, Inc anuncia su visión de expansión de la plataforma de terapia con células T CAR hacia las enfermedades autoinmunes	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Mustang Bio Announces Closing of $4 Million Public Offering	02/05
Mustang Bio, Inc. announced that it has received $3.3 million in funding	02/05
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	30/04
Mustang Bio Announces Pricing of $4 Million Public Offering	30/04
Mustang Bio : Results of Operations and Financial Condition - Form 8-K	29/04
Mustang Bio, Inc. announced that it expects to receive $3.3 million in funding	29/04
North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions	15/04
Mustang Bio : Costs Associated with Exit/Disposal - Form 8-K	12/04
Mustang Bio : Corporate Presentation	01/04
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28/03
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28/03
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	11/03
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
City of Hope-developed chimeric antigen receptor T cell therapy shows clinical activity in patients with aggressive brain tumors in a Phase 1 trial	08/03
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma	07/03
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma	07/03
Mustang Bio : Corporate Presentation	01/03
Mustang Bio, Inc Appoints James Murphy as Interim Chief Financial Officer	25/01
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference	11/01
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer	12/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Mustang Bio, Inc.

Acciones

MBIO

US62818Q2030

Otros idiomas

Filtros